-+ 0.00%
-+ 0.00%
-+ 0.00%

MEDICUS PHARMA ADVANCES TEVERELIX® PROGRAM TOWARDS REGISTRATIONAL DEVELOPMENT TARGETING HIGH CARDIOVASCULAR-RISK PROSTATE CANCER PATIENTS WITH KEY EUROPEAN SUBMISSION

Reuters·06/08/2026 11:30:01

Please log in to view news